Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.75 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.75 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.74 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.74 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.74 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.64 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.64 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.64 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.64 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.64 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.64 |
| ▸ | MGLL | Q99685 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5507892 | 0.95 | MAPT (0.69) | MAPTALOX12HDAC3HDAC1HDAC2 | |
| SCHEMBL9507460 | 0.94 | HDAC1 (0.69) | MAPTALOX12HDAC3HDAC1HDAC2 | |
| SCHEMBL11617043 | 0.94 | HDAC1 (0.69) | MAPTALOX12HDAC3HDAC1HDAC2 | |
| SCHEMBL11610572 | 0.94 | HDAC1 (0.69) | MAPTALOX12HDAC3HDAC1HDAC2 | |
| SCHEMBL5694358 | 0.94 | HDAC1 (0.69) | MAPTALOX12HDAC3HDAC1HDAC2 | |
| SCHEMBL11615321 | 0.94 | HDAC1 (0.69) | MAPTALOX12HDAC3HDAC1HDAC2 | |
| SCHEMBL11617021 | 0.94 | HDAC1 (0.69) | MAPTALOX12HDAC3HDAC1HDAC2 | |
| SCHEMBL11615696 | 0.94 | HDAC1 (0.69) | MAPTALOX12HDAC3HDAC1HDAC2 | |
| SCHEMBL11614664 | 0.94 | HDAC1 (0.69) | MAPTALOX12HDAC3HDAC1HDAC2 | |
| SCHEMBL11048249 | 0.94 | HDAC1 (0.69) | MAPTALOX12HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115594603-A | Method for preparing N-tert-butyl-4-aminobenzamide by using microchannel reactor | 湖北师范大学（CN） | 2023-01-13 | — | — | CN | claimed |
| EP-1332363-A4 | DETECTION OF NEURODEGENERATIVE DISORDERS | DOUBLE KAY (AU) | 2007-08-29 | — | — | EP | claimed |
| US-7005546-B2 | Acetamidobenzamide compounds for neurodegenerative disorders | RENOVIS, INC. (US) | 2006-02-28 | — | — | US | claimed |
| US-20050260577-A1 | Detection of neurodegenerative disorders | POWMRI LIMITED (AU) | 2005-11-24 | — | — | US | claimed |
| EP-1581202-A2 | METHODS FOR THE TREATMENT OF PAIN AND TRAUMATIC INJURY USING BENZAMIDES AND COMPOSITIONS CONTAINING THE SAME | Renovis, Inc. (US) | 2005-10-05 | — | — | EP | claimed |
| US-20040167226-A1 | Methods for the treatment of pain and traumatic injury using benzamides and compositions containing the same | RENOVIS, INC. | 2004-08-26 | — | — | US | claimed |
| WO-2004060286-A2 | METHODS FOR THE TREATMENT OF PAIN AND TRAUMATIC INJURY USING BENZAMIDES AND COMPOSITIONS CONTAINING THE SAME | RENOVIS, INC. (US) | 2004-07-22 | — | — | WO | claimed |
| EP-1332363-A1 | DETECTION OF NEURODEGENERATIVE DISORDERS | UNISEARCH LIMITED (AU) | 2003-08-06 | — | — | EP | claimed |
| WO-2002031499-A1 | DETECTION OF NEURODEGENERATIVE DISORDERS | UNISEARCH LIMITED (AU) | 2002-04-18 | — | — | WO | claimed |
| CN-1073552-C | Benzamides for neurodegenerative disorder treatment | CENTAUR PHARMACEUTICALS INC (US) | 2001-10-24 | — | — | CN | claimed |
| EP-0819113-B1 | BENZAMIDES FOR NEURODEGENERATIVE DISORDER TREATMENT | CENTAUR PHARMACEUTICALS INC (US) | 2001-06-27 | — | — | EP | claimed |
| EP-1079820-A1 | BENZAMIDE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 2001-03-07 | — | — | EP | claimed |
| US-6194465-B1 | ADMINISTERING ACETAMIDO-, NITRO-, OR AMINO-MONO- OR DISUBSTITUTED N-ALKYL BENZAMIDE COMPOUNDS SUCH AS N-TERT-BUTYL-4-ACETAMIDOBENZAMIDE FOR PROPHLAXIS OR TREATMENT OF AN INFLAMMATORY BOWEL CONDITION IN A PATIENT | CENTAUR PHARMACEUTICALS, INC. | 2001-02-27 | — | — | US | claimed |
| WO-1999059569-A1 | BENZAMIDE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-11-25 | — | — | WO | claimed |
| CN-1182416-A | Benzamides for neurodegenerative disorder treatment | CENTAUR PHARMACUETICALS INC (US) | 1998-05-20 | — | — | CN | claimed |
| EP-0819113-A1 | BENZAMIDES FOR NEURODEGENERATIVE DISORDER TREATMENT | CENTAUR PHARMACEUTICALS, INC. (US) | 1998-01-21 | — | — | EP | claimed |
| WO-1996031462-A1 | BENZAMIDES FOR NEURODEGENERATIVE DISORDER TREATMENT | CENTAUR PHARMACEUTICALS, INC. (US) | 1996-10-10 | — | — | WO | claimed |
| EP-0345551-B1 | EASILY FLOWABLE DELAYED CRYSTALLISING POLYARYLENE SULFIDE-MIXTURES | BAYER AG (DE) | 1993-09-08 | — | — | EP | claimed |
| EP-4345091-A1 | BENZOIC ACID DERIVATIVES, METHODS AND USES THEREOF | Faculdade de Farmácia da Universidade de Lisboa (PT) | 2024-04-03 | — | — | EP | disclosed |
| US-4097489-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167226-A1 | Methods for the treatment of pain and traumatic injury using benzamides and compositions containing the same | CNR1, NAA50, CNR2 | MAPT 2635/4885ALOX12 1520/4885HDAC3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.